沛嘉医疗涨超4%国家药监局近日受理TaurusTrioTM经导管主动脉瓣系统注册申请

动脉网
24 Apr

沛嘉医疗-B股价涨超4%,因其开发的TaurusTrioTM经导管主动脉瓣系统注册申请获中国国家药监局受理,该系统专为治疗主动脉瓣反流设计,将优先审批。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10